

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

210864Orig1s000

LABELING

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SESQUIENT safely and effectively. See full prescribing information for SESQUIENT.

SESQUIENT (fosphenytoin sodium) injection, for intravenous use
Initial U.S. Approval: 1996

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES

See full prescribing information for complete boxed warning.

- The rate of intravenous SESQUIENT administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute in adults because of the risk of severe hypotension and cardiac arrhythmias.
- Careful cardiac monitoring is needed during and after administering intravenous SESQUIENT.
- Reduction in rate of administration or discontinuation of dosing may be needed (2.3, 2.4, 5.2).

INDICATIONS AND USAGE

SESQUIENT is indicated:

- for the treatment of generalized tonic-clonic status epilepticus in adult patients (1)
- prevention and treatment of seizures occurring during neurosurgery in adult patients (1)
- for short-term substitution for oral phenytoin in patients 2 years of age and older. SESQUIENT should be used only when oral phenytoin administration is not possible. (1)

DOSAGE AND ADMINISTRATION

- The dose, concentration, and infusion rate of SESQUIENT should always be expressed as phenytoin sodium equivalents (PE) (2.1)
- For Status Epilepticus in Adults:
 - Loading dose is 15 mg PE/kg to 20 mg PE/kg at a rate of 100 mg PE/min to 150 mg PE/min (2.3)
- For Non-emergent Loading and Maintenance Dosing:
 - Adult loading dose is 10 mg PE/kg to 20 mg PE/kg given intravenously; initial maintenance dose is 4 mg PE/kg to 6 mg PE/kg/day in divided doses (2.4)
 - Pediatric loading dose is 10 mg PE/kg to 15 mg PE/kg given intravenously; initial maintenance dose is 2 mg PE/kg to 4 mg PE/kg every 12 hours. Because of the betadex sulfobutyl ether sodium ingredient in SESQUIENT, administration rate in pediatric patients should not exceed 0.4 mg PE/kg/min. The rate of administration of intravenous SESQUIENT in pediatric patients differs from that of other intravenous fosphenytoin products. (2.4)

DOSAGE FORMS AND STRENGTHS

Injection: 50 mg phenytoin sodium equivalents (PE)/mL available as:

- 500 mg PE per 10 mL (50 mg PE/mL) in single-dose vials (3)
- 100 mg PE per 2 mL (50 mg PE/mL) in single-dose vials (3)

CONTRAINDICATIONS

- Hypersensitivity to fosphenytoin, phenytoin, other hydantoin, or any of the inactive ingredients in SESQUIENT (4)
- Sinus bradycardia, sino-atrial block, second and third-degree A-V block, and Adams-Stokes syndrome (4)
- A history of prior acute hepatotoxicity attributable to SESQUIENT, fosphenytoin, or phenytoin (4, 5.7)
- Coadministration with delavirdine (4)

WARNINGS AND PRECAUTIONS

- *Dosing Errors* Do not confuse the amount of drug to be given in PE with the concentration of the drug in the vial. Ensure the appropriate volume is withdrawn from the vial when preparing for administration. (5.1)
- *Withdrawal Precipitated Seizure* May precipitate status epilepticus. Dose reductions or discontinuation should be done gradually. (5.3)
- *Serious Dermatologic Reactions* Discontinue at the first sign of a rash, unless clearly not drug-related. If signs or symptoms suggest SJS/TEN, SESQUIENT should not be resumed; consider alternative therapy. (5.4)
- *Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan hypersensitivity* If signs or symptoms of hypersensitivity are present, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established. (5.5)
- *Hematopoietic Complications* If occurs, follow-up observation is indicated and an alternative antiepileptic treatment should be used. (5.9)

ADVERSE REACTIONS

Most common adverse reactions (incidence $\geq 10\%$) are:

- *Adults* pruritus, nystagmus, dizziness, somnolence, and ataxia
- *Pediatrics* vomiting, nystagmus, and ataxia (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Sedor Pharmaceuticals, LLC, at 1-610-455-2180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Multiple drug interactions because of extensive plasma protein binding, saturable metabolism, and potent induction of hepatic enzymes (7.1, 7.2)

USE IN SPECIFIC POPULATIONS

- *Pregnancy*: Phenytoin (the active metabolite of SESQUIENT) prenatal exposure may increase risks for congenital malformations and other adverse developmental outcomes (5.15, 8.1)
- *Renal and/or Hepatic Impairment or Hypoalbuminemia*: Monitor unbound phenytoin concentrations in these patients. Because of accumulation of sulfobutylether beta-cyclodextrin sodium salt, closely monitor serum creatinine levels in patients with severe renal impairment. (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Administration Instructions to Avoid Dosing Errors
- 2.2 Preparation
- 2.3 Status Epilepticus in Adults
- 2.4 Non-emergent Loading and Maintenance Dosing in Adult and Pediatric Patients
- 2.5 Laboratory Tests and Monitoring Levels
- 2.6 Parenteral Substitution for Oral Phenytoin Therapy
- 2.7 Dosing in Patients with Renal or Hepatic Impairment or Hypoalbuminemia
- 2.8 Dosing in Geriatrics
- 2.9 Dosing during Pregnancy

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Dosing Errors
- 5.2 Cardiovascular Risk Associated with Rapid Infusion
- 5.3 Withdrawal Precipitated Seizure, Status Epilepticus
- 5.4 Serious Dermatologic Reactions
- 5.5 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity
- 5.6 Hypersensitivity
- 5.7 Angioedema
- 5.8 Hepatic Injury
- 5.9 Hematopoietic Complications
- 5.10 Sensory Disturbances
- 5.11 Local Toxicity (Including Purple Glove Syndrome)
- 5.12 Phosphate Load
- 5.13 Renal or Hepatic Disease or Hypoalbuminemia

- 5.14 Exacerbation of Porphyrria
- 5.15 Teratogenicity and Other Harm to the Newborn
- 5.16 Hyperglycemia
- 5.17 Serum Phenytoin Levels above Therapeutic Range

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Drugs that Affect Phenytoin or SESQUIENT
- 7.2 Drugs Affected by Phenytoin or SESQUIENT
- 7.3 Drug/Laboratory Test Interactions

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal and/or Hepatic Impairment, or Hypoalbuminemia
- 8.7 Use in Patients with Decreased CYP2C9 Function

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics
- 12.5 Pharmacogenomics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES

The rate of intravenous SESQUIENT administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute in adults because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous SESQUIENT. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed [see Warnings and Precautions (5.2) and Dosage and Administration (2.3, 2.4)].

1 INDICATIONS AND USAGE

SESQUIENT is indicated:

- for the treatment of generalized tonic-clonic status epilepticus in adult patients
- for the prevention and treatment of seizures occurring during neurosurgery in adult patients.
- for short-term substitution for oral phenytoin in patients 2 years of age and older. SESQUIENT should be used only when oral phenytoin administration is not possible [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions to Avoid Dosing Errors

Use caution when administering SESQUIENT because of the risk of dosing errors [see Warnings and Precautions (5.1)].

Phenytoin Sodium Equivalents (PE)

The dose, concentration, and infusion rate of SESQUIENT should always be expressed as phenytoin sodium equivalents (PE). There is no need to perform molecular weight-based adjustments when converting between fosphenytoin and phenytoin sodium doses. SESQUIENT should always be prescribed and dispensed in phenytoin sodium equivalent units (PE). The amount and concentration of fosphenytoin is always expressed in terms of mg of phenytoin sodium equivalents (mg PE).

Concentration of 50 mg PE/mL

Do not confuse the concentration of SESQUIENT with the total amount of drug in the vial.

Errors, including fatal overdoses, have occurred when the concentration of the vial (50 mg PE/mL) was misinterpreted to mean that the total content of the vial was 50 mg PE. These errors have resulted in two- or tenfold overdoses of SESQUIENT since each of the vials actually contains a total of 100 mg PE (2 mL) or 500 mg PE (10 mL). Ensure the appropriate volume of SESQUIENT is withdrawn from the vial when preparing the

dose for administration. Attention to these details may prevent some SESQUIENT medication errors from occurring.

2.2 Preparation

Prior to intravenous infusion, dilute SESQUIENT in 5% dextrose or 0.9% saline solution for injection to a concentration ranging from 1.5 mg PE/mL to 25 mg PE/mL. The maximum concentration of SESQUIENT in any solution should be 25 mg PE/mL. When SESQUIENT is given as an intravenous infusion, SESQUIENT needs to be diluted and should only be administered at a rate not exceeding 150 mg PE/min in adults or 0.4 mg PE/kg/min in pediatric patients 2 years to less than 17 years of age.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Drug product with particulate matter or discoloration should not be used.

The diluted SESQUIENT solution is stable for 4 hours at room temperature.

For single-dose only. After opening, any unused product should be discarded.

2.3 Status Epilepticus in Adults

- Because of the risk of hypotension and cardiac arrhythmias, the rate of administration for SESQUIENT should be no greater than 150 mg PE/min in adults [*see Warnings and Precautions (5.2)*]. Continuous monitoring of the electrocardiogram, blood pressure, and respiratory function is essential, and the patient should be observed throughout the period where maximal serum phenytoin concentrations occur, approximately 10 to 20 minutes after the end of SESQUIENT infusions.
- Because the full antiepileptic effect of phenytoin, whether given as SESQUIENT or parenteral phenytoin, is not immediate, other measures, including concomitant administration of an intravenous benzodiazepine, will usually be necessary for the control of status epilepticus.
- The loading dose should be followed by maintenance doses of either SESQUIENT or phenytoin [*see Dosage and Administration (2.4)*].
- If administration of SESQUIENT does not terminate seizures, the use of other anticonvulsants and other appropriate measures should be considered.
- See Table 1 for status epilepticus dosing in adult patients.

Table 1. Status Epilepticus Loading Dosages in Adult Patients

Population	Dosage	Infusion Rate
Adults (17 years of age and older)	15 mg PE/kg to 20 mg PE/kg	100 mg PE/min to 150mg PE/min, do not exceed a maximum rate of 150 mg PE/min

2.4 Non-emergent Loading and Maintenance Dosing in Adult and Pediatric Patients

- Rate of Administration
 - Adult Patients (17 years of age and older): Because of the risk of hypotension and cardiac arrhythmias, the rate of administration for SESQUIENT should not exceed 150 mg PE/min in adults.
 - Pediatric Patients (2 years to less than 17 years of age): Because of the betadex sulfobutyl ether sodium ingredient in SESQUIENT, the rate of administration for SESQUIENT should not exceed 0.4 mg PE/kg/min in pediatric patients. The rate of administration of intravenous SESQUIENT in pediatric patients differs from that of other intravenous fosphenytoin products.
- Monitoring: Continuous monitoring of the electrocardiogram, blood pressure, and respiratory function is essential, and the patient should be observed throughout the period where maximal serum phenytoin concentrations occur (approximately 10 to 20 minutes after the end of SESQUIENT infusions).
- After the initial maintenance dose, subsequent maintenance doses should be individualized by monitoring serum phenytoin concentrations to achieve a target therapeutic concentration of phenytoin [see *Dosage and Administration (2.5) and Warnings and Precautions (5.17)*].
- See Table 2 and Table 3 for adult and pediatric non-emergent loading and maintenance dosing, respectively.

Table 2. Non-emergent Loading Dosages

Population	Dosage	Infusion Rate
Adult	10 mg PE/kg to 20 mg PE/kg	Not to exceed a maximum rate of 150 mg PE/min
Pediatric (2 years to less than 17 years of age)	10 mg PE/kg to 15 mg PE/kg	Not to exceed a maximum rate of 0.4 mg PE/kg/min

Table 3. Maintenance Dosages

Population	Dosage	Infusion Rate
Adult	Initial Maintenance Dosage: 4 mg PE/kg/day to 6 mg PE/kg/day in divided doses	Not to exceed a maximum rate of 150 mg PE/min
Pediatric (2 years to less than 17 years of age)	Initial Maintenance Dosage: 2 mg PE/kg to 4 mg PE/kg (dose given 12 hours after the loading dose)	Not to exceed a maximum rate of 0.4 mg PE/kg/min
	Maintenance Dosage after Initial Maintenance Dosage: 4 mg PE/kg/day to 8 mg PE/kg/day in divided doses (continued every 12 hours after initial maintenance dose)	Not to exceed a maximum rate of 0.4 mg PE/kg/min

2.5 Laboratory Tests and Monitoring Levels

Laboratory Tests

SESQUIENT (or phenytoin) doses are usually selected to attain therapeutic serum total phenytoin concentrations of 10 to 20 mcg/mL (unbound phenytoin concentrations of 1 to 2 mcg/mL). Following SESQUIENT administration, it is recommended that phenytoin concentrations not be monitored until conversion to phenytoin is essentially complete. This occurs within approximately 2 hours after the end of intravenous infusion. Prior to complete conversion, commonly used immunoanalytical techniques, such as TDx[®]/TDxFLx[™] (fluorescence polarization) and Emit[®] 2000 (enzyme multiplied), may significantly overestimate serum phenytoin concentrations because of cross-reactivity with fosphenytoin. The error is dependent on serum phenytoin and fosphenytoin concentration (influenced by SESQUIENT dose, route and rate of administration, and time of sampling relative to dosing), and analytical method. Chromatographic assay methods accurately quantitate phenytoin concentrations in biological fluids in the presence of fosphenytoin. Prior to complete conversion, blood samples for phenytoin monitoring should be collected in tubes containing EDTA as an anticoagulant to minimize *ex vivo* conversion of fosphenytoin to phenytoin. However, even with specific assay methods, phenytoin concentrations measured before conversion of fosphenytoin is complete will not reflect phenytoin concentrations ultimately achieved.

Monitoring Levels

Trough levels provide information about clinically effective serum level range and are obtained just prior to the patient's next scheduled dose. Peak levels indicate an individual's threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration. Therapeutic effect without clinical signs of toxicity occurs more often with serum total phenytoin concentrations between 10 and 20 mcg/mL (unbound phenytoin concentrations of 1 to 2 mcg/mL), although some mild cases of tonic-clonic (grand mal) epilepsy may be controlled with lower serum levels of phenytoin. In patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of unbound phenytoin concentrations may be more relevant [*see Dosage and Administration (2.7)*].

2.6 Parenteral Substitution for Oral Phenytoin Therapy

Because of the risks of cardiac and local toxicity associated with intravenous SESQUIENT, oral phenytoin should be used whenever possible. When treatment with oral phenytoin is not possible, SESQUIENT can be substituted for oral phenytoin at the same total daily phenytoin sodium equivalents (PE) dose. Dilantin capsules are approximately 90% bioavailable by the oral route. Phenytoin, derived from administration of SESQUIENT, is 100% bioavailable by the intravenous route. For this reason, serum phenytoin concentrations may increase modestly when SESQUIENT is substituted for oral phenytoin sodium therapy. The rate of administration for SESQUIENT should be no greater than 150 mg PE/min in adults and 0.4 mg PE/kg/min in pediatric patients.

2.7 Dosing in Patients with Renal or Hepatic Impairment or Hypoalbuminemia

Because the fraction of unbound phenytoin (the active metabolite of SESQUIENT) is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. After intravenous SESQUIENT administration to patients with renal and/or hepatic disease, or in those with hypoalbuminemia, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance. This has the potential to increase the frequency and severity of adverse events [*see Warnings and Precautions (5.13)*].

Closely monitor serum creatinine levels and estimated glomerular filtration rate (eGFR) in patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) receiving intravenous SESQUIENT. If serum creatinine level increases occur, consider changing to oral phenytoin [*see Use in Specific Populations (8.6)*].

2.8 Dosing in Geriatrics

The clearance of phenytoin (the active metabolite of SESQUIENT) is decreased slightly in elderly patients and lower or less frequent dosing may be required [see *Clinical Pharmacology (12.3)*].

2.9 Dosing during Pregnancy

Decreased serum concentrations of phenytoin (the active metabolite of SESQUIENT) may occur during pregnancy because of altered phenytoin pharmacokinetics [see *Clinical Pharmacology (12.3)*]. Periodic measurement of serum phenytoin concentrations should be performed during pregnancy, and the SESQUIENT dosage should be adjusted as necessary. Postpartum restoration of the original dosage will probably be indicated [see *Use in Specific Populations (8.1)*]. Because of potential changes in protein binding during pregnancy, the monitoring of phenytoin serum levels should be based on the unbound fraction.

3 DOSAGE FORMS AND STRENGTHS

Injection:

- 500 mg PE per 10 mL (50 mg PE/mL) clear, colorless, sterile solution in single-dose vials
- 100 mg PE per 2 mL (50 mg PE/mL) clear, colorless, sterile solution in single-dose vials

4 CONTRAINDICATIONS

SESQUIENT is contraindicated in patients with:

- A history of hypersensitivity to fosphenytoin, phenytoin, other hydantoins, or any of the inactive ingredients in SESQUIENT [see *Warnings and Precautions (5.6)*].
- Sinus bradycardia, sino-atrial block, second and third degree A-V block, or Adams-Stokes syndrome because of the effect of parenteral phenytoin or SESQUIENT on ventricular automaticity.
- A history of prior acute hepatotoxicity attributable to SESQUIENT, fosphenytoin, or phenytoin [see *Warnings and Precautions (5.8)*].
- Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

5 WARNINGS AND PRECAUTIONS

5.1 Dosing Errors

Phenytoin Sodium Equivalents (PE)

Do not confuse the amount of drug to be given in PE with the concentration of the drug in the vial.

Doses of SESQUIENT are always expressed in terms of milligrams of phenytoin sodium equivalents (mg PE). 1 mg PE is equivalent to 1 mg phenytoin sodium.

Do not, therefore, make any adjustment in the recommended doses when substituting SESQUIENT for phenytoin sodium or vice versa. For example, if a patient is receiving 1000 mg PE of SESQUIENT, that is equivalent to 1000 mg of phenytoin sodium.

Concentration of 50 mg PE/mL

Medication errors associated with fosphenytoin have resulted in patients receiving the wrong dose of fosphenytoin. SESQUIENT is marketed in 2 mL vials containing a total of 100 mg PE and 10 mL vials containing a total of 500 mg PE. The concentration of each vial is 50 mg PE/mL. Errors have occurred when the concentration of the vial (50 mg PE/mL) was misinterpreted to mean that the total content of the vial was 50 mg PE. These errors have resulted in two- or ten-fold overdoses of fosphenytoin since each vial actually contains a total of 100 mg PE or 500 mg PE. In some cases, ten-fold overdoses were associated with fatal outcomes. To help minimize confusion, the prescribed dose of SESQUIENT should always be expressed in milligrams of phenytoin equivalents (mg PE) [*see Dosage and Administration (2.1)*]. Additionally, when ordering and storing SESQUIENT, consider displaying the total drug content (i.e., 100 mg PE/ 2 mL or 500 mg PE/ 10 mL) instead of concentration in computer systems, pre-printed orders, and automated dispensing cabinet databases to help ensure that total drug content can be clearly identified. Care should be taken to ensure the appropriate volume of SESQUIENT is withdrawn from the vial when preparing the drug for administration. Attention to these details may prevent some SESQUIENT medication errors from occurring.

5.2 Cardiovascular Risk Associated with Rapid Infusion

Rapid intravenous (IV) administration of SESQUIENT increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Cardiac arrhythmias have included bradycardia, heart block, QT interval prolongation, ventricular tachycardia, and ventricular fibrillation which have resulted in asystole, cardiac arrest, and death. Severe complications are most commonly encountered in critically ill patients, elderly patients, and patients with hypotension and severe myocardial insufficiency. However, cardiac events have also been reported in adults and children without underlying cardiac disease or comorbidities and at recommended doses and infusion rates.

The rate of IV SESQUIENT administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute in adults. Rates above 0.4 mg PE/kg/min in pediatric patients have not been studied [*see Dosage and Administration (2.3, 2.4) and Use in Specific Populations (8.4)*].

Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate.

As non-emergency therapy, IV SESQUIENT should be administered more slowly. Because of the risks of cardiac and local toxicity associated with IV SESQUIENT, oral phenytoin should be used whenever possible.

Because adverse cardiovascular reactions have occurred during and after infusions, careful cardiac and respiratory monitoring is needed during and after the administration of IV SESQUIENT. Reduction in rate of administration or discontinuation of dosing may be needed.

5.3 Withdrawal Precipitated Seizure, Status Epilepticus

Antiepileptic drugs should not be abruptly discontinued because of the possibility of increased seizure frequency, including status epilepticus. When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative antiepileptic medication arises, this should be done gradually. However, in the event of an allergic or hypersensitivity reaction, rapid substitution of alternative therapy may be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class.

5.4 Serious Dermatologic Reactions

SESQUIENT can cause severe cutaneous adverse reactions (SCARs), which may be fatal. Reported reactions in phenytoin (the active metabolite of SESQUIENT)-treated patients have included toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), acute generalized exanthematous pustulosis (AGEP), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) [*see Warnings and Precautions (5.5)*]. The onset of symptoms is usually within 28 days, but can occur later. SESQUIENT should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest a severe cutaneous adverse reaction, use of this drug should not be resumed and alternative therapy should be considered. If a rash occurs, the patient should be evaluated for signs and symptoms of SCARs.

Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. In addition, retrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCAR in carriers of the decreased function CYP2C9*3 variant, which has also been associated with decreased clearance of phenytoin. Consider avoiding SESQUIENT as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.

Should SESQUIENT be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range [*see Use in Specific Populations (8.7)*].

The use of HLA-B*1502 or CYP2C9 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management. The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied.

5.5 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including phenytoin and fosphenytoin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. SESQUIENT should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

5.6 Hypersensitivity

SESQUIENT and other hydantoin are contraindicated in patients who have experienced phenytoin hypersensitivity [see *Contraindications (4)*]. Additionally, consider alternatives to structurally similar drugs such as carboxamides (e.g., carbamazepine), barbiturates, succinimides, and oxazolidinediones (e.g., trimethadione) in these same patients. Similarly, if there is a history of hypersensitivity reactions to these structurally similar drugs in the patient or immediate family members, consider alternatives to SESQUIENT.

5.7 Angioedema

Angioedema has been reported in patients treated with phenytoin and fosphenytoin in the postmarketing setting. SESQUIENT should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur. SESQUIENT should be discontinued permanently if a clear alternative etiology for the reaction cannot be established.

5.8 Hepatic Injury

Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin (the active metabolite of SESQUIENT). These events may be part of the spectrum of DRESS or may occur in isolation [see *Warnings and Precautions (5.5)*]. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, SESQUIENT should be immediately discontinued and not re-administered.

5.9 Hematopoietic Complications

Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin (the active metabolite of SESQUIENT). These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression.

There have been a number of reports that have suggested a relationship between phenytoin and the development of lymphadenopathy (local or generalized), including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs resembling DRESS [see *Warnings and Precautions (5.5)*].

In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs.

5.10 Sensory Disturbances

Severe burning, itching, and/or paresthesia were reported by 7 of 16 normal volunteers administered intravenous (IV) fosphenytoin at a dose of 1200 mg PE at the maximum rate of administration (150 mg PE/min). The severe sensory disturbance lasted from 3 to 50 minutes in 6 of these subjects and for 14 hours in the seventh subject. In some cases, milder sensory disturbances persisted for as long as 24 hours. The location of the discomfort varied among subjects with the groin mentioned most frequently as an area of discomfort. In a

separate cohort of 16 normal volunteers (taken from 2 other studies) who were administered IV fosphenytoin at a dose of 1200 mg PE at the maximum rate of administration (150 mg PE/min), none experienced severe disturbances, but most experienced mild to moderate itching or tingling. Patients administered fosphenytoin at doses of 20 mg PE/kg at 150 mg PE/min are expected to experience discomfort of some degree. The occurrence and intensity of the discomfort can be lessened by slowing or temporarily stopping the infusion. The effect of continuing infusion unaltered in the presence of these sensations is unknown. No permanent sequelae have been reported thus far. The pharmacologic basis for these positive sensory phenomena is unknown, but other phosphate ester drugs, which deliver smaller phosphate loads, have been associated with burning, itching, and/or tingling predominantly in the groin area.

5.11 Local Toxicity (Including Purple Glove Syndrome)

Edema, discoloration, and pain distal to the site of injection (described as “purple glove syndrome”) have also been reported following peripheral intravenous injection of fosphenytoin. This may or may not be associated with extravasation. The syndrome may not develop for several days after injection.

5.12 Phosphate Load

The phosphate load provided by SESQUIENT (0.0037 mmol phosphate/mg PE SESQUIENT) should be considered when treating patients who require phosphate restriction, such as those with severe renal impairment.

5.13 Renal or Hepatic Disease or Hypoalbuminemia

Because the fraction of unbound phenytoin (the active metabolite of SESQUIENT) is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. After intravenous administration to patients with renal and/or hepatic disease, or in those with hypoalbuminemia, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance. This has the potential to increase the frequency and severity of adverse events.

5.14 Exacerbation of Porphyria

In view of isolated reports associating phenytoin (the active metabolite of SESQUIENT) with exacerbation of porphyria, caution should be exercised in using SESQUIENT in patients suffering from this disease.

5.15 Teratogenicity and Other Harm to the Newborn

SESQUIENT may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin (the active metabolite of SESQUIENT) may increase the risks for congenital malformations and other adverse development outcomes [see *Use in Specific Populations (8.1)*].

Increased frequencies of major malformations (such as orofacial clefts and cardiac defects), and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including neuroblastoma. The

overall incidence of malformations for children of epileptic women treated with antiepileptic drugs, including phenytoin, during pregnancy is about 10%, or two- to three-fold that in the general population.

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth.

5.16 Hyperglycemia

Hyperglycemia, resulting from the inhibitory effect of phenytoin (the active metabolite of SESQUIENT) on insulin release, has been reported. Phenytoin may also raise the serum glucose concentrations in diabetic patients.

5.17 Serum Phenytoin Levels above Therapeutic Range

Serum levels of phenytoin (the active metabolite of SESQUIENT) sustained above the therapeutic range may produce confusional states referred to as “delirium,” “psychosis,” or “encephalopathy,” or rarely, irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. SESQUIENT dose reduction is indicated if serum levels are excessive; if symptoms persist, administration of SESQUIENT should be discontinued.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Cardiovascular Risk Associated with Rapid Infusion [*see Warnings and Precautions (5.2)*]
- Withdrawal Precipitated Seizure, Status Epilepticus [*see Warnings and Precautions (5.3)*]
- Serious Dermatologic Reactions [*see Warnings and Precautions (5.4)*]
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [*see Warnings and Precautions (5.5)*]
- Hypersensitivity [*see Warnings and Precautions (5.6)*]
- Angioedema [*see Warnings and Precautions (5.7)*]
- Hepatic Injury [*see Warnings and Precautions (5.8)*]
- Hematopoietic Complications [*see Warnings and Precautions (5.9)*]
- Sensory Disturbances [*see Warnings and Precautions (5.10)*]
- Local Toxicity (Including Purple Glove Syndrome) [*see Warnings and Precautions (5.11)*]
- Exacerbation of Porphyria [*see Warnings and Precautions (5.14)*]
- Teratogenicity and Other Harm to the Newborn [*see Warnings and Precautions (5.15)*]
- Hyperglycemia [*see Warnings and Precautions (5.16)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The more important adverse clinical reactions caused by the intravenous (IV) use of SESQUIENT or phenytoin are cardiovascular collapse and/or central nervous system depression. Hypotension can occur when either drug is administered rapidly by the IV route. The rate of administration is very important; for SESQUENT, the rate for adult patients should not exceed 150 mg PE/min. The rate of administration of SESQUIENT in pediatric patients is limited to 0.4 mg PE/kg/min because the safety of IV administration of the betadex sulfobutyl ether sodium ingredient in SESQUIENT at a faster rate has not been established [see *Warnings and Precautions (5.2) and Use in Specific Populations (8.4)*].

The data presented below were obtained from a formulation of fosphenytoin injection that does not contain betadex sulfobutyl ether sodium [see *Clinical Studies (14)*].

The adverse reactions most commonly observed with the use of fosphenytoin injection in clinical trials were nystagmus, dizziness, pruritus, somnolence, and ataxia. With one exception, these reactions are commonly associated with the administration of IV phenytoin. Pruritus, however, was seen much more often following fosphenytoin injection administration compared to phenytoin injection. These reactions were dose and rate related; most alert patients (41 of 64; 64%) administered doses of ≥ 15 mg PE/kg at 150 mg PE/min experienced discomfort of some degree. These sensations, generally described as itching, burning, or tingling, were usually not at the infusion site. The location of the discomfort varied with the groin mentioned most frequently as a site of involvement. The paresthesia and pruritus were transient events that occurred within several minutes of the start of infusion and generally resolved within 10 minutes after completion of fosphenytoin infusion. Some patients experienced symptoms for hours. These reactions did not increase in severity with repeated administration. Concurrent adverse events or clinical laboratory change suggesting an allergic process were not seen [see *Warnings and Precautions (5.10)*]. Approximately 2% of the 859 patients who received fosphenytoin injection in premarketing clinical trials discontinued treatment because of an adverse event. The adverse events most commonly associated with withdrawal were pruritus (0.5%), hypotension (0.3%), and bradycardia (0.2%).

Dose and Rate Dependency of Adverse Reactions Following IV Fosphenytoin Injection

The incidence of adverse reactions tended to increase as both dose and infusion rate increased. In particular, at doses of ≥ 15 mg PE/kg and rates ≥ 150 mg PE/min, transient pruritus, tinnitus, nystagmus, somnolence, and ataxia occurred 2 to 3 times more often than at lower doses or rates.

Incidence in Controlled Clinical Trials - IV Administration to Adult Patients with Epilepsy or Neurosurgical Patients

Table 4 lists adverse reactions that occurred in at least 2% of adult patients treated with IV fosphenytoin at the maximum dose and rate in a randomized, double-blind, controlled clinical trial where the rates for phenytoin and fosphenytoin administration would have resulted in equivalent systemic exposure to phenytoin.

TABLE 4. Adverse Reaction Incidence Following IV Administration at the Maximum Dose and Rate to Adult Patients with Epilepsy or Neurosurgical Patients (Events in at Least 2% of Fosphenytoin-Treated Patients)

BODY SYSTEM	IV Fosphenytoin	IV Phenytoin ¹
Adverse Event	N=90	N=22
BODY AS A WHOLE		
Pelvic Pain	4	0
Asthenia	2	0
Back Pain	2	0
Headache	2	5

BODY SYSTEM	IV Fosphenytoin	IV Phenytoin ¹
Adverse Event	N=90	N=22
CARDIOVASCULAR		
Hypotension	8	9
Vasodilatation	6	5
Tachycardia	2	0
DIGESTIVE		
Nausea	9	14
Tongue Disorder	4	0
Dry Mouth	4	5
Vomiting	2	9
NERVOUS		
Nystagmus	44	59
Dizziness	31	27
Somnolence	20	27
Ataxia	11	18
Stupor	8	5
Incoordination	4	5
Paresthesia	4	0
Extrapyramidal Syndrome	4	0
Tremor	3	9
Agitation	3	0
Hypesthesia	2	9
Dysarthria	2	0
Vertigo	2	0
Brain Edema	2	5
SKIN AND APPENDAGES		
Pruritus	49	5
SPECIAL SENSES		
Tinnitus	9	9
Diplopia	3	0
Taste Perversion	3	0
Amblyopia	2	9
Deafness	2	0

¹ The study was not designed to assess comparative safety.

Incidence in Clinical Trials - IV Administration to Pediatric Patients

The overall incidence of adverse reactions and the types of adverse reactions seen were similar among children and adults treated with fosphenytoin injection. In an open-label, safety, tolerability, and pharmacokinetic study of fosphenytoin in pediatric patients (including age 2 through age 16), the following adverse reactions occurred at a frequency of at least 5% in 96 patients treated with IV fosphenytoin: vomiting (21%), nystagmus (18%), ataxia (10%), fever (8%), nervousness (7%), pruritus (6%), somnolence (6%), hypotension (5%), and rash (5%).

Adverse Events During Clinical Trials in Adult and Pediatric Patients

Fosphenytoin injection has been administered to approximately 900 individuals during clinical trials. Adverse events seen at least twice are listed in the following, except those already included in previous tables and listings. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 individuals; infrequent adverse events are those occurring in 1/100 to 1/1000 individuals.

Body as a Whole: *Frequent:* fever, injection-site reaction, infection, chills, face edema, injection-site pain; *Infrequent:* sepsis, injection-site inflammation, injection-site edema, injection-site hemorrhage, flu syndrome, malaise, generalized edema, shock, photosensitivity reaction, cachexia, cryptococcosis.

Cardiovascular: *Frequent:* hypertension; *Infrequent:* cardiac arrest, migraine, syncope, cerebral hemorrhage, palpitation, sinus bradycardia, atrial flutter, bundle branch block, cardiomegaly, cerebral infarct, postural hypotension, pulmonary embolus, QT interval prolongation, thrombophlebitis, ventricular extrasystoles, congestive heart failure.

Digestive: *Frequent:* constipation; *Infrequent:* dyspepsia, diarrhea, anorexia, gastrointestinal hemorrhage, increased salivation, liver function tests abnormal, tenesmus, tongue edema, dysphagia, flatulence, gastritis, ileus.

Endocrine: *Infrequent:* diabetes insipidus.

Hematologic and Lymphatic: *Infrequent:* thrombocytopenia, anemia, leukocytosis, cyanosis, hypochromic anemia, leukopenia, lymphadenopathy, petechia.

Laboratory Test Abnormality: Phenytoin (the active metabolite of SESQUIENT) may cause increased serum levels of glucose and alkaline phosphatase.

Metabolic and Nutritional: *Frequent:* hypokalemia; *Infrequent:* hyperglycemia, hypophosphatemia, alkalosis, acidosis, dehydration, hyperkalemia, ketosis.

Musculoskeletal: *Frequent:* myasthenia; *Infrequent:* myopathy, leg cramps, arthralgia, myalgia.

Nervous: *Frequent:* reflexes increased, speech disorder, dysarthria, intracranial hypertension, thinking abnormal, nervousness; *Infrequent:* confusion, twitching, Babinski sign positive, circumoral paresthesia, hemiplegia, hypotonia, convulsion, extrapyramidal syndrome, insomnia, meningitis, depersonalization, CNS depression, depression, hypokinesia, hyperkinesia, paralysis, psychosis, aphasia, emotional lability, coma, hyperesthesia, myoclonus, personality disorder, acute brain syndrome, encephalitis, subdural hematoma, encephalopathy, hostility, akathisia, amnesia, neurosis.

Respiratory: *Frequent:* pneumonia; *Infrequent:* pharyngitis, sinusitis, hyperventilation, rhinitis, apnea, aspiration pneumonia, asthma, dyspnea, atelectasis, cough increased, sputum increased, epistaxis, hypoxia, pneumothorax, hemoptysis, bronchitis.

Skin and Appendages: *Frequent:* rash; *Infrequent:* maculopapular rash, urticaria, sweating, skin discoloration, contact dermatitis, pustular rash, skin nodule.

Special Senses: *Infrequent:* visual field defect, eye pain, conjunctivitis, photophobia, hyperacusis, mydriasis, parosmia, ear pain, taste loss.

Urogenital: *Infrequent:* urinary retention, oliguria, dysuria, vaginitis, albuminuria, genital edema, kidney failure, polyuria, urethral pain, urinary incontinence, vaginal moniliasis.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of fosphenytoin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole: Anaphylaxis, angioedema [*see Warnings and Precautions (5.7)*]

Laboratory Test Abnormality: Phenytoin or SESQUIENT may decrease serum concentrations of T4. It may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may also cause increased serum levels of gamma glutamyl transpeptidase (GGT).

Nervous System Disorders: Dyskinesia

7 DRUG INTERACTIONS

Fosphenytoin is extensively bound to human plasma proteins. Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin. Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering SESQUIENT with other drugs that significantly bind to serum albumin. The most significant drug interactions following administration of SESQUIENT are expected to occur with drugs that interact with phenytoin. Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement. Phenytoin is primarily metabolized by hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19 and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity. Monitoring of phenytoin serum levels is recommended when a drug interaction is suspected.

Phenytoin or SESQUIENT is a potent inducer of hepatic drug-metabolizing enzymes.

7.1 Drugs that Affect Phenytoin or SESQUIENT

Table 5 includes commonly occurring drug interactions that affect phenytoin (the active metabolite of SESQUIENT) concentrations. However, this list is not intended to be inclusive or comprehensive. Individual prescribing information from relevant drugs should be consulted.

The addition or withdrawal of these agents in patients on phenytoin therapy may require an adjustment of the phenytoin dose to achieve optimal clinical outcome.

Table 5. Drugs That Affect Phenytoin Concentrations	
Interacting Agent	Examples
Drugs that may increase phenytoin serum levels	
Antiepileptic drugs	Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate
Azoles	Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole
Antineoplastic agents	Capecitabine, fluorouracil
Antidepressants	Fluoxetine, fluvoxamine, sertraline
Gastric acid reducing agents	H ₂ antagonists (cimetidine), omeprazole
Sulfonamides	Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazoletrimethoprim
Other	Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin
Drugs that may decrease phenytoin serum levels	
Antineoplastic agents usually in combination	Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate
Antiviral agents	Fosamprenavir, nelfinavir, ritonavir
Antiepileptic drugs	Carbamazepine, vigabatrin
Other	Chronic alcohol abuse, diazepam, diazoxide, folic acid, reserpine, rifampin, St. John's wort, ^a theophylline
Drugs that may either increase or decrease phenytoin serum levels	
Antiepileptic drugs	Phenobarbital, valproate sodium, valproic acid

^aThe induction potency of St. John's wort may vary widely based on preparation.

7.2 Drugs Affected by Phenytoin or SESQUIENT

Table 6 includes commonly occurring drug interactions affected by phenytoin (the active metabolite of SESQUIENT). However, this list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted. The addition or withdrawal of phenytoin during concomitant therapy with these agents may require adjustment of the dose of these agents to achieve optimal clinical outcome.

Table 6: Drugs Affected by Phenytoin	
Interacting Agent	Examples
Drugs whose efficacy is impaired by phenytoin	
Azoles	Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole
Antineoplastic agents	Irinotecan, paclitaxel, teniposide

Table 6: Drugs Affected by Phenytoin	
Interacting Agent	Examples
Delavirdine	Phenytoin can substantially reduce the concentrations of delavirdine. This can lead to loss of virologic response and possible resistance [see <i>Contraindications (4)</i>].
Neuromuscular blocking agents	Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. Whether or not phenytoin has the same effect on other non-depolarizing agents is unknown. <i>Prevention or Management:</i> Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher.
Warfarin	Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin.
Other	Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D
Drugs whose level is decreased by phenytoin	
Antiepileptic drugs ^a	Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine
Antilipidemic agents	Atorvastatin, fluvastatin, simvastatin
Antiviral agents	Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir
Calcium channel blockers	Nifedipine, nimodipine, nisoldipine, verapamil
Other	Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, folic acid, methadone, mexiletine, praziquantel, quetiapine

^a The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable.

7.3 Drug/Laboratory Test Interactions

Care should be taken when using immunoanalytical methods to measure serum phenytoin concentrations following SESQUIENT administration.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as SESQUIENT, during pregnancy. Physicians are advised to recommend that pregnant patients taking SESQUIENT enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website <http://www.aedpregnancyregistry.org/>.

Risk Summary

In humans, prenatal exposure to phenytoin (the active metabolite of SESQUIENT) may increase the risks for congenital malformations and other adverse development outcomes. An increased incidence of major malformations (such as orofacial clefts and cardiac defects) and abnormalities characteristic of fetal hydantoin syndrome (dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [including microcephaly], and cognitive deficits) has been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including neuroblastoma, in children whose mothers received phenytoin during pregnancy.

Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other manifestations of developmental toxicity (including embryofetal death, growth impairment, and behavioral abnormalities) in multiple species at clinically relevant doses [*see Data*].

In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The overall incidence of malformations for children of epileptic women treated with antiepileptic drugs (phenytoin and/or others) during pregnancy is about 10%, or two- to three-fold that in the general population.

Clinical Considerations

Disease-associated maternal risk

An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage [*see Dosage and Administration (2.5, 2.9)*]. However, postpartum restoration of the original dosage will probably be indicated.

Fetal/Neonatal adverse reactions

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin *in utero*. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth.

Data

Animal data

Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased fetal growth. Malformations (including craniofacial, cardiovascular, neural, limb, and digit abnormalities) were observed in rats, rabbits, and mice at doses as low as 100, 75, and 12.5 mg/kg, respectively.

8.2 Lactation

Risk Summary

It is not known whether fosphenytoin is secreted in human milk. Following administration of phenytoin (the active metabolite of SESQUIENT), phenytoin is secreted in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SESQUIENT and any potential adverse effects on the breastfed infant from SESQUIENT or from the underlying maternal condition.

8.4 Pediatric Use

Safety and effectiveness of SESQUIENT in pediatric patients for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery have not been established. The rate of administration of SESQUIENT in pediatric patients is limited to 0.4 mg PE/kg/min because the safety of intravenous (IV) administration of the betadex sulfobutyl ether sodium ingredient in SESQUIENT at a faster rate has not been established. This maximum rate of 0.4 mg PE/kg/min does not allow for adequate treatment of status epilepticus or seizures occurring during neurosurgery. In addition, rapid IV administration of fosphenytoin increases the risk of adverse cardiovascular reactions; however, these events have also been reported at or below the recommended infusion rate. *[see Dosage and Administration (2.4) and Warnings and Precautions (5.2)]*.

The safety and effectiveness of SESQUIENT for the short-term substitution of oral phenytoin have been established in pediatric patients 2 years of age and older. Use of SESQUIENT in these patients is supported by evidence from adequate and well-controlled safety studies in adults comparing IV fosphenytoin to IV phenytoin; pharmacokinetic data in healthy adults comparing SESQUIENT to IV fosphenytoin; and safety data of betadex sulfobutyl ether sodium in pediatric patients 2 years of age and older. There are no data on the safety of betadex sulfobutyl ether sodium in pediatric patients below 2 years of age. Safety of SESQUIENT for short-term substitution for oral phenytoin in patients below the 2 years of age has not been established.

8.5 Geriatric Use

No systematic studies in geriatric patients have been conducted. Phenytoin clearance tends to decrease with increasing age *[see Clinical Pharmacology (12.3)]*. Lower or less frequent dosing may be required *[see Clinical Pharmacology (12.3) and Dosage and Administration (2.8)]*.

8.6 Renal and/or Hepatic Impairment, or Hypoalbuminemia

The liver is the site of biotransformation *[see Clinical Pharmacology (12.3)]*. Patients with impaired liver function, elderly patients, or those who are gravely ill may show early toxicity.

Because the fraction of unbound phenytoin (the active metabolite of SESQUIENT) is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients.

After IV administration to patients with renal and/or hepatic disease, or in those with hypoalbuminemia, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance. This has the potential to increase the frequency and severity of adverse events.

Sulfobutylether beta-cyclodextrin sodium salt is known to accumulate in patients with moderate to severe renal impairment. Closely monitor serum creatinine levels in patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) receiving intravenous SESQUIENT. If serum creatinine level increases occur, consider changing to oral phenytoin.

8.7 Use in Patients with Decreased CYP2C9 Function

Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL. If early signs of dose-related central nervous system (CNS) toxicity develop, serum concentrations should be checked immediately [*see Clinical Pharmacology (12.5)*].

10 OVERDOSAGE

Nausea, vomiting, lethargy, tachycardia, bradycardia, asystole, cardiac arrest, hypotension, syncope, hypocalcemia, metabolic acidosis, and death have been reported in cases of overdosage with phenytoin and fosphenytoin.

Because SESQUIENT is a prodrug of phenytoin, the following information about phenytoin overdosage may be helpful. Initial symptoms of acute phenytoin toxicity are nystagmus, ataxia, and dysarthria. Other signs include tremor, hyperreflexia, lethargy, slurred speech, nausea, vomiting, coma, and hypotension. Death is caused by respiratory and circulatory depression. The lethal dose of phenytoin in adults is estimated to be 2 to 5 grams. The lethal dose in pediatrics is not known.

There are marked variations among individuals with respect to serum phenytoin concentrations where toxicity occurs. Lateral gaze nystagmus usually appears at 20 µg/mL, ataxia at 30 µg/mL, and dysarthria and lethargy appear when the serum concentration is over 40 µg/mL. However, phenytoin concentrations as high as 50 µg/mL have been reported without evidence of toxicity. As much as 25 times the therapeutic phenytoin dose has been taken, resulting in serum phenytoin concentrations over 100 µg/mL, with complete recovery. Irreversible cerebellar dysfunction and atrophy have been reported after overdosage.

Formate and phosphate are metabolites of SESQUIENT and therefore may contribute to signs of toxicity following overdosage. Signs of formate toxicity are similar to those of methanol toxicity and are associated with severe anion-gap metabolic acidosis. Large amounts of phosphate, delivered rapidly, could potentially cause hypocalcemia with paresthesia, muscle spasms, and seizures. Ionized free calcium levels can be measured and, if low, used to guide treatment.

Treatment

Treatment is nonspecific since there is no known antidote to SESQUIENT or phenytoin overdosage.

The adequacy of the respiratory and circulatory systems should be carefully observed, and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin (the active metabolite of

SESQUIENT) is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in children.

In acute overdosage the possibility of other CNS depressants, including alcohol, should be borne in mind.

11 DESCRIPTION


SESQUIENT (Fosphenytoin Sodium Injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. 1.5 mg of fosphenytoin sodium is equivalent to 1 mg phenytoin sodium, and is referred to as 1 mg phenytoin sodium equivalents (PE). The amount and concentration of fosphenytoin is always expressed in terms of mg PE.

The pharmacological class of the fosphenytoin sodium is hydantoin derivative, and the therapeutic class is anticonvulsant.

SESQUIENT is supplied as a clear, colorless, sterile solution in single-dose vials containing 100 mg PE/2 mL or 500 mg PE/10 mL, for intravenous administration. Each mL contains 50 mg PE (equivalent to 75 mg fosphenytoin sodium or 46 mg phenytoin) and the following inactive ingredients: 100 mg of betadex sulfobutyl ether sodium and 2.42 mg of tromethamine in water for injection, adjusted to pH 7.6 to 8.2 with either hydrochloric acid or sodium hydroxide.

FDA approved impurity specification for phenytoin differs from USP. FDA approved pH specification differs from USP.

The chemical name of fosphenytoin sodium is 5,5-diphenyl-3-[(phosphonoxy)methyl]-2,4-imidazolidinedione disodium salt. The molecular structure of fosphenytoin sodium is:



The molecular weight of fosphenytoin sodium is 406.24.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Fosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects are attributable to phenytoin. The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.

12.3 Pharmacokinetics

Fosphenytoin

Absorption

Intravenous: When SESQUIENT is administered by intravenous (IV) infusion, maximum plasma fosphenytoin concentrations are achieved at the end of the infusion.

Distribution

Fosphenytoin is extensively bound (95% to 99%) to human plasma proteins, primarily albumin. Binding to plasma proteins is saturable with the result that the percent bound decreases as total fosphenytoin concentrations increase. Fosphenytoin displaces phenytoin from protein binding sites. The volume of distribution of fosphenytoin increases with SESQUIENT dose and rate, and ranges from 4.3 to 10.8 liters.

Elimination

The conversion half-life of fosphenytoin to phenytoin is approximately 15 minutes.

Metabolism

Following parenteral administration of SESQUIENT, fosphenytoin is converted to the anticonvulsant phenytoin. The mechanism of fosphenytoin conversion has not been determined, but phosphatases probably play a major role. Fosphenytoin is metabolized to phenytoin, phosphate, and formate. For every mmol of fosphenytoin administered, one mmol of phenytoin is produced. The hydrolysis of fosphenytoin to phenytoin yields two metabolites, phosphate and formaldehyde. Formaldehyde is subsequently converted to formate, which is in turn metabolized via a folate dependent mechanism. Although phosphate and formaldehyde (formate) have potentially important biological effects, these effects typically occur at concentrations considerably in excess of those obtained when SESQUIENT is administered under conditions of use recommended in this labeling.

Excretion

Fosphenytoin is not excreted in urine.

Phenytoin (after SESQUIENT administration)

The pharmacokinetics of fosphenytoin following IV administration of SESQUIENT are complex, and when used in an emergency setting (e.g., status epilepticus), differences in rate of availability of phenytoin could be critical. Studies have therefore empirically determined an infusion rate for SESQUIENT that gives a rate and extent of phenytoin systemic availability similar to that of a 50 mg/min phenytoin sodium infusion. A dose of 15 to 20 mg PE/kg of SESQUIENT infused at 100 to 150 mg PE/min yields plasma free phenytoin concentrations over time that approximate those achieved when an equivalent dose of phenytoin sodium (e.g., parenteral DILANTIN[®]) is administered at 50 mg/min [*see Dosage and Administration (2.3) and Warnings and Precautions (5.2)*].




FIGURE 1. Mean plasma unbound phenytoin concentrations following IV administration of 1200 mg PE fosphenytoin infused at 100 mg PE/min (triangles) or 150 mg PE/min (squares) and 1200 mg Dilantin infused at 50 mg/min (diamonds) to healthy subjects (N = 12). Inset shows time course for the entire 96-hour sampling period.

Following administration of single IV fosphenytoin doses of 400 to 1200 mg PE, mean maximum total phenytoin concentrations increase in proportion to dose, but do not change appreciably with changes in infusion rate. In contrast, mean maximum unbound phenytoin concentrations increase with both dose and rate.

Absorption

Fosphenytoin is completely converted to phenytoin following IV administration, with a half-life of approximately 15 minutes. Fosphenytoin is also completely converted to phenytoin following IM administration and plasma total phenytoin concentrations peak in approximately 3 hours.

Distribution

Phenytoin is highly bound to plasma proteins, primarily albumin, although to a lesser extent than fosphenytoin. In the absence of fosphenytoin, approximately 12% of total plasma phenytoin is unbound over the clinically relevant concentration range. However, fosphenytoin displaces phenytoin from plasma protein binding sites. This increases the fraction of phenytoin unbound (up to 30% unbound) during the period required for conversion of fosphenytoin to phenytoin (approximately 0.5 to 1 hour post infusion).

Elimination

Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.

Metabolism

Phenytoin derived from administration of fosphenytoin is extensively metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and to a lesser extent by CYP2C19. Phenytoin hepatic metabolism is

saturable, and following administration of single IV fosphenytoin doses of 400 to 1200 mg PE, total and unbound phenytoin AUC values increase disproportionately with dose.

Excretion

Phenytoin derived from administration of fosphenytoin is excreted in urine primarily as 5-(p-hydroxyphenyl)-5phenylhydantoin and its glucuronide; little unchanged phenytoin (1%–5% of the fosphenytoin dose) is recovered in urine.

Specific Populations

Age: Geriatric Population

The effect of age on the pharmacokinetics of fosphenytoin was evaluated in patients 5 to 98 years of age. Patient age had no significant impact on fosphenytoin pharmacokinetics. Phenytoin clearance tends to decrease with increasing age (20% less in patients over 70 years of age relative to that in patients 20–30 years of age).

Sex/Race

Gender and race have no significant impact on fosphenytoin or phenytoin pharmacokinetics.

Renal or Hepatic Impairment

Increased fraction of unbound phenytoin (the active metabolite of SESQUIENT) in patients with renal or hepatic disease, or in those with hypoalbuminemia has been reported.

Pregnancy

It has been reported in the literature that the plasma clearance of phenytoin (the active metabolite of SESQUIENT) generally increased during pregnancy, reached a peak in the third trimester and returned to the level of pre-pregnancy after few weeks or months of delivery [*see Dosage and Administration (2.9)*].

Drug Interaction Studies

Phenytoin derived from administration of fosphenytoin is extensively metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and to a lesser extent by CYP2C19 [*see Drug Interactions (7.1, 7.2)*]. No drugs are known to interfere with the conversion of fosphenytoin to phenytoin. Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.

The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and fosphenytoin were concurrently administered in single submaximal doses.

12.5 Pharmacogenomics

CYP2C9 activity is decreased in individuals with genetic variants such as the CYP2C9*2 and CYP2C9*3 alleles. Carriers of variant alleles, resulting in intermediate (e.g., *1/*3, *2/*2) or poor metabolism (e.g., *2/*3, *3/*3) have decreased clearance of phenytoin. Other decreased or nonfunctional CYP2C9 alleles may also result in decreased clearance of phenytoin (e.g., *5, *6, *8, *11).

The prevalence of the CYP2C9 poor metabolizer phenotype is approximately 2-3% in the White population, 0.5-4% in the Asian population, and <1% in the African American population. The CYP2C9 intermediate

phenotype prevalence is approximately 35% in the White population, 24% in the African American population, and 15-36% in the Asian population [see *Warnings and Precautions (5.4) and Use in Specific Populations (8.7)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis [see *Warnings and Precautions (5.8)*]

The carcinogenic potential of fosphenytoin has not been assessed. In carcinogenicity studies, phenytoin (active metabolite of fosphenytoin) was administered in the diet to mice (10, 25, or 45 mg/kg/day) and rats (25, 50, or 100 mg/kg/day) for 2 years. The incidences of hepatocellular tumors were increased in male and female mice at the highest dose. No increases in tumor incidence were observed in rats. The highest doses tested in these studies were associated with peak plasma phenytoin levels below human therapeutic concentrations.

In carcinogenicity studies reported in the literature, phenytoin was administered in the diet for 2 years at doses up to 600 ppm (approximately 90 mg/kg/day) to mice and up to 2400 ppm (approximately 120 mg/kg/day) to rats. The incidences of hepatocellular tumors were increased in female mice at all but the lowest dose tested. No increases in tumor incidence were observed in rats.

Mutagenesis

An increase in structural chromosome aberrations were observed in cultured V79 Chinese hamster lung cells exposed to fosphenytoin in the presence of metabolic activation. No evidence of mutagenicity was observed in bacteria (Ames test) or Chinese hamster lung cells *in vitro*, and no evidence for clastogenic activity was observed in an *in vivo* mouse bone marrow micronucleus assay.

Impairment of Fertility

Fosphenytoin was administered to male and female rats during mating and continuing in females throughout gestation and lactation at doses of 50 mg PE/kg or higher. No effects on fertility were observed in males. In females, altered estrous cycles, delayed mating, prolonged gestation length, and developmental toxicity were observed at all doses, which were associated with maternal toxicity. The lowest dose tested is approximately 40% of the maximum human loading dose on a mg/m² basis.

14 CLINICAL STUDIES

The efficacy of SESQUIENT is based upon bioavailability studies comparing SESQUIENT to another intravenous fosphenytoin that does not contain betadex sulfobutyl ether sodium. The content of betadex sulfobutyl ether sodium present in SESQUIENT limits use in the pediatric population to non-urgent loading dosing and short-term maintenance dosing as replacement for oral phenytoin in patients older than 2 years [see *Indications and Usage (1), Dosage and Administration (2.4), and Use in Specific Populations (8.4)*].

Infusion tolerance was evaluated in clinical studies. One double-blind study in adult patients assessed infusion-site tolerance of equivalent loading doses (15–20 mg PE/kg) of IV fosphenytoin infused at 150 mg PE/min or phenytoin infused at 50 mg/min. The study demonstrated better local tolerance (pain and burning at the infusion site), fewer disruptions of the infusion, and a shorter infusion period for fosphenytoin-treated patients (Table 7).

TABLE 7. Infusion Tolerance of Equivalent Loading Doses of IV Fosphenytoin and IV Phenytoin

	IV fosphenytoin N=90	IV Phenytoin N=22
Local Intolerance	9% ^a	90%
Infusion Disrupted	21%	67%
Average Infusion Time	13 min	44 min

^aPercent of patients

Fosphenytoin-treated patients, however, experienced more systemic sensory disturbances [see *Warnings and Precautions (5.10)*]. Infusion disruptions in fosphenytoin-treated patients were primarily due to systemic burning, pruritus, and/or paresthesia while those in phenytoin-treated patients were primarily due to pain and burning at the infusion site (see Table 7).

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

SESQUIENT is a clear, colorless, sterile solution supplied as follows:

500 mg PE/10 mL vial (50 mg PE/mL). Package contains 10 vials (NDC 80674-210-10).

100 mg PE/2 mL vial (50 mg PE/mL). Package contains 25 vials (NDC 80674-102-25).

SESQUIENT should always be prescribed in phenytoin sodium equivalents (PE) [see *Dosage and Administration (2.1)* and *Warnings and Precautions (5.1)*].

1.5 mg of fosphenytoin sodium is equivalent to 1 mg phenytoin sodium, and is referred to as 1 mg PE. The amount and concentration of fosphenytoin is always expressed in terms of mg of phenytoin sodium equivalents (PE). Fosphenytoin's weight is expressed as phenytoin sodium equivalents to avoid the need to perform molecular weight-based adjustments when substituting fosphenytoin for phenytoin or vice versa.

16.2 Storage and Handling

Store SESQUIENT at room temperature 20°C to 25°C (68°F to 77°F). Temperature excursions are permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Vials that develop particulate matter should not be used.

Injection vials are single-dose only. After opening, any unused product should be discarded.

17 PATIENT COUNSELING INFORMATION

Cardiovascular Risk Associated with Rapid Infusion

Inform patients that rapid intravenous administration of SESQUIENT increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Cardiac arrhythmias have

included bradycardia, heart block, ventricular tachycardia, and ventricular fibrillation which have resulted in asystole, cardiac arrest, and death. Patients should report cardiac signs or symptoms to their healthcare provider [see *Warnings and Precautions (5.2)*].

Withdrawal of Antiepileptic Drugs

Advise patients not to discontinue use of SESQUIENT without consulting with their healthcare provider. SESQUIENT should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus [see *Warnings and Precautions (5.3)*].

Serious Dermatologic Reactions

Advise patients of the early signs and symptoms of severe cutaneous adverse reactions and to report any occurrence immediately to a physician [see *Warnings and Precautions (5.4)*].

Potential Signs of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Other Systemic Reactions

Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and petechial or purpuric hemorrhage, and in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. Advise the patient that, because these signs and symptoms may signal a serious reaction, that they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use [see *Warnings and Precautions (5.4, 5.5, 5.6, 5.8, 5.9)*].

Angioedema

Advise patients to discontinue SESQUIENT and seek immediate medical care if they develop signs or symptoms of angioedema such as facial, perioral, or upper airway swelling [see *Warnings and Precautions (5.7)*].

Hyperglycemia

Advise patients that SESQUIENT may cause an increase in blood glucose levels [see *Warnings and Precautions (5.16)*].

Effects of Alcohol Use and Other Drugs and Over-the-Counter Drug Interactions

Caution patients against the use of other drugs or alcoholic beverages without first seeking their healthcare provider's advice [see *Drug Interactions (7.1, 7.2)*].

Inform patients that certain over-the-counter medications (e.g., cimetidine and omeprazole), vitamins (e.g., folic acid), and herbal supplements (e.g., St. John's wort) can alter their phenytoin levels.

Use in Pregnancy

Inform pregnant women and women of childbearing potential that use of SESQUIENT during pregnancy can cause fetal harm, including an increased risk for cleft lip and/or cleft palate (oral clefts), cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities (including microcephaly), and cognitive deficits [see *Warnings and Precautions (5.15)*]. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who are not planning a pregnancy to use effective contraception while using SESQUIENT, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy [see *Drug Interactions (7.2)*].

Instruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy [*see Use in Specific Populations (8.1, 8.2)*].

Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy [*see Use in Specific Populations (8.1)*].

Manufactured by:
Emergent BioSolutions Inc
Baltimore, MD 21224

Manufactured for:
Sedor Pharmaceuticals LLC
Paoli, PA 19301

Barcode

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NICHOLAS A KOZAUER
11/05/2020 05:12:01 PM